Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
How did they promote it? They only said their drug is identical to brand coreg
Are hikma and reddy more scared based on today’s TEVA loss?
Teva used “skinny label” that excluded hypertension and lost Made 75 million off coreg. Have to pay back 235 million. Wow. Does this apply to amarin?
My point is they cannot legally switch it unless you issue another script specifically for omega 3 with DHA/EPA mixture.
Are you sure about that? That’s actually illegal
They cannot substitute automatically unless you issue a new script.
Vascepa and lovaza are not identical and generic lovaza is not generic for Vascepa.
I don’t know
I deny them a switch.
But attempts to switch to Lovaza are rare in my practice
You know, the reimbursement will be the – you know, the key factor as it is for any drug, you know, being launched in Europe. You know, thus far, our pricing outside of the U.S. has been, you know, higher on a net basis than our pricing inside the U.S. and I think that's largely because when we launched in the United States, we’re launching for a limited triglyceride lowering indication, which was a genericized market. You know, without outcomes data and [indiscernible] these other markets were going with the first and only drug for, you know, cardiovascular risk reduction for our indication and we're doing that with pronounced outcomes data.
Some of the countries in Europe allow you to get started relatively quickly, in particular, you know, Germany. Others require that you have the price negotiated before you launch. So, you know, a combination of the target physicians being more with specialists proportionately compared to what's in the United States and its sort of rolling reimbursement approval. We think a lot will allow us to have a very efficient launch where we're getting into some countries trying to get profitable in those countries and then, you know, launching other countries after we've already had some of that, you know, momentum started.
I think also compared to the US, it'll be nice to be going in and having reimbursement, you know, from the start. When we're launching, you know, we will have the reimbursement in the countries in which we are launching in rather than having that, you know, be a prolonged processes that was in the early days for VASCEPA, you know, in the United States. So, you know, there's still a lot of work to be done, but, you know, thus far things are progressing well and we are, you know, very excited about what continues to appear to be an opportunity measured in the billion.
He said the US price is based in marine
EU price will be higher because of reduce it results. It will save EU a lot of money.
If you read JT transcript from 2 weeks ago, he said that vascepa price in europe will be higher than in US
Because no generic will challenge it since they already have a backdoor. Having reduce it invalidated in USA will not make a difference for generics.
They cannot invalidate Reduce-it patents
Each tine they try to reject it. I suspect once generic comes out, it will disappear.
They don’t unless they ask with preauthorization
It is still a rumor
BO rumor that is most likely BS made up story.
Stick to accounting. Agree.
What a dumb comment
“Patients will be invalidated”
You are wrong. Stick with accounting.
Looks like BB is dumping the stock
I am calling Melania this morning.
You are correct sir. Statin and Vascepa combo is useless and not protected from generics. This will not save amarin US sales.
Crestor (generic) $15 for 90 days with no insurance using good rx.
Statin plus Vascepa would have to be super cheap for insurance to pay for it.
Insurances don’t care. They will pay for cheapest option. Statin vascepa combo has no chance to be profitable
Insurance companies cover combo drugs only if they are equal or lower in price than 2 drugs combined. Otherwise they say: use 2 separate drugs.
No easy way out of this mess. That’s why we are at $4
If amarin makes a combo, generic copies it right away.
Generics have no patent for CV / CAD but they will eat Amarin’s lunch anyway.
All statins are generic
Any pharma can copy it, including vascepa statin combo.
Insurances will not be willing to pay for it unless it is dirt cheap
Both statins and vascepa have no patents. They are generic. Generics can make the same pill
Is that legal by SEC?
How about If there is nothing to report?
All may be true and I personally believe it is but we need to complete these studies first before we can promote anything in regards to Covid.
So what are the studies supporting Vascepa treatment for Covid 19?
FDA approved $TEVA generic Vascepa (ICOSAPENT ETHYL) 500MG & 1GM.
I am not a lawyer so not sure. Maybe if you can find a similar case from the past?
Treating triglycerides for 12 weeks will come at 0 percent.
I suspected that. It appears that generics can take 100 percent Reduce-it patients and still have a good legal standing.
I looked and it is not mentioned there
The 5 percent that generic are allowed for skinny label that you are keep mentioning...how did you get that number?
Is there any reference?
Losartan, valsartan and olmsartan are all available
Here is chemistry professor Niels Harrit from University of Copenhagen Denmark
It is in Danish with English subtitles